RNA
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Atrium Therapeutics, Inc. (RNA) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Growth (D-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | B (3.3) | D- (1.1) | D+ (1.7) | D (1.4) | C+ (2.6) | C- (2.0) |
| 2026-11-07 | B (3.4) | F (0.6) | F (0.5) | D+ (1.6) | C+ (2.7) | D+ (1.8) |
| 2026-10-31 | B (3.3) | F (0.6) | F (0.6) | D+ (1.6) | C+ (2.7) | D+ (1.7) |
| 2026-10-24 | B (3.3) | F (0.6) | F (0.5) | D (1.4) | C+ (2.6) | D+ (1.7) |
| 2026-10-17 | B (3.3) | F (0.5) | F (0.5) | D (1.5) | C+ (2.6) | D+ (1.7) |